Pfizer’s Dividend Yield vs. Growth: Is It Time to Rebalance Your Portfolio?



Pfizer Inc. (PFE), striving to set the standard for quality, safety, and value in the discovery, development, and manufacture of biopharmaceutical products, reported solid second-quarter 2024 earnings and raised guidance for the full year. In the second quarter of 2024, the company’s revenues increased 2.1% year-over-year to $13.28 billion. This was PFE’s first quarter of […]



Source link

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *